Company Description
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers.
It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers.
The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients.
The company was founded in 2008 and is headquartered in Irving, Texas.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jun 18, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,846 |
| CEO | David Halbert |
Contact Details
Address: 750 West John Carpenter Freeway, Suite 800 Irving, Texas 75039 United States | |
| Phone | 866 771 8946 |
| Website | carislifesciences.com |
Stock Details
| Ticker Symbol | CAI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $21.00 |
| CIK Code | 2019410 |
| CUSIP Number | 142152107 |
| ISIN Number | US1421521071 |
| Employer ID | 85-2077369 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Dean Halbert M.D. | Chairman, Chief Executive Officer and Founder |
| Brian J. Brille J.D. | Executive Vice Chairman and Executive Vice President |
| Dr. David Spetzler M.B.A., M.S., Ph.D. | President |
| J. Russel Denton | Senior Vice President, General Counsel and Secretary |
| Luke Power | Senior Vice President, Chief Financial Officer and Chief Accounting Officer |
| Jon Mark Harmon | Senior Vice President and Chief Operations Officer |
| Dr. Valeriy Domenyuk | Senior Vice President and Chief Technology Officer |
| Dr. Milan Radovich Ph.D. | Senior Vice President and Chief Scientific Officer |
| Ginger Appleberry J.D. | Senior Vice President, Deputy General Counsel and Chief Compliance Officer |
| Narendra Chokshi | Senior Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | 8-K | Current Report |
| Apr 23, 2026 | ARS | Filing |
| Apr 23, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2026 | SCHEDULE 13G/A | Filing |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 3, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |